SEATTLE, April 3, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. KAa clinical-stage biotechnology company focused on developing novel immunotherapies in oncology that address the immune resistance of cancer, today announced that Shawn Iadonato, Ph.D., CEO, at the 22nd annual Needham Healthcare Conference will give a lecture, which will take place virtually from April 17 -20.02.2023. The company management is also available for virtual one-on-one meetings.

Case: 22nd Annual Needham Virtual Healthcare Conference
Date: Tuesday April 18, 2023
Time: 12:45 p.m. – 1:25 p.m. EST

Replay of the webcast presentation will be available on the Events & Presentations section of the company’s website.

About Kineta
Kineta KA is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its innate immunity expertise and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges in current cancer therapy. For more information on Kineta, see www.kinetabio.comand continue to follow Kineta Twitter, LinkedIn And Facebook.

KVA12123 (formerly referred to as KVA12.1) is intended to be a differentiated VISTA-blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is a fully human-made IgG1 monoclonal antibody designed to bind to VISTA through a unique epitope. KVA12123 could be an effective immunotherapy for many types of cancer, including NSCLC (lung), colorectal, renal cell, head and neck and ovarian cancer. These initial target indications represent a significant unmet medical need with a large global commercial opportunity for KVA12123.

Cautionary Statements Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Use of words such as, but not limited to,…